Tariff volatility and geopolitical disruption are exposing healthcare and life sciences companies to group action claims arising from supply chain decisions.

When the US Supreme Court struck down the IEEPA tariffs in February 2026, most companies focused on the refund opportunity. Within days, claimant lawyers had reframed the same ruling as a class action opportunity, with at least five putative nationwide class actions filed before the end of that month.

For global supply chains already under pressure from geopolitical volatility, the message was clear: the supply chain is no longer just an operational concern.

The expansion of coordinated claims mechanisms and increasingly sophisticated litigation funding make supply chain decisions a growing source of litigation risk. Clifford Chance’s A Global View on Group Action Litigation: What Lies Ahead? examines both trends and their implications for companies.

How supply chain disruption can lead to group action claims

Traditional legal risk assessment focuses on the probability of an adverse outcome and potential liability. That lens is too narrow when the originating event is a supply chain failure or a tariff-driven commercial decision. Rather, group action exposure in this sector is driven by a set of dynamics that supply chain disruption can trigger or accelerate:

• Scale: products reach large patient populations. A single supplier failure, raw material shortage, or tariff-driven cost increase can affect an entire product category at a speed that outpaces internal response time.
• Standardisation: uniform product practices and disclosures give claimants a common factual foundation for coordinated claims, but inconsistent supplier terms and gaps in contractual coverage across the supply chain make it harder to demonstrate a coherent defence when those claims arrive.
• Funding: third party funding and claimant firm strategies are increasingly sophisticated, enabling novel theories of liability to be resourced rapidly, including around decisions companies considered routine.
• Regulatory overlap: supply chain failures, safety signals, and tariff-driven pricing gaps can also attract parallel scrutiny from regulators, payors, and public bodies.
• Reputation: in the healthcare and life sciences sector, allegations involving patient harm or data misuse can have a disproportionate impact on brand and market position, regardless of legal merits.

For legal teams, this means supply chain risk cannot be assessed in isolation from litigation risk. An operational decision taken today (for example to accept a supplier term, absorb a tariff cost, or defer a contract renegotiation) may become evidence in group proceedings tomorrow.

Developments in Germany and other jurisdictions

Germany offers the clearest illustration of this pattern for companies with European supply chain exposure, and the dynamics it reveals, around funding, evidentiary focus, and contractual exposure, are now playing out, in varying forms, across other major jurisdictions.

In Germany, mass claims litigation is accelerating, driven by litigation funding, coordinated claimant strategies, and legal frameworks supporting large-scale individual actions, bundling, and collective redress. Product liability, GDPR, and greenwashing claims are all rising, and the evidentiary focus is increasingly on what companies knew and whether their contracts reflected that knowledge. Thorough agreements and effective renegotiation mechanisms (including provisions that anticipate regulatory and geopolitical change) can help mitigate dispute risk. Documentation and renegotiation rights may also provide important evidence in subsequent proceedings.

The same three levers are moving in claimants' favour elsewhere: funder-friendly rule changes, procedural simplification, and new theories of liability attaching to familiar commercial decisions.

A practical framework for internal engagement

The following questions can help translate supply chain risk into C-suite language and bridge to understanding of group action exposure:

• Patient reach: if a supply chain failure or tariff-driven cost decision were substantiated as a systemic issue, how many patients or users could realistically be affected?
• Contractual foundation: do your supplier agreements and procurement terms allocate geopolitical and tariff risk clearly? Do they include renegotiation mechanisms for circumstances that could not reasonably have been anticipated at signing?
• Funding likelihood: would a supply chain failure or related commercial decision produce a sufficiently large, clearly defined pool of affected parties to make funding commercially attractive?
• Regulatory amplification: is parallel scrutiny from regulators, payors, or public authorities likely, particularly where the supply chain issue touches on product safety, sourcing practices, or pricing?
• Reputational impact: how would allegations, even if unproven, interact with trust, brand and market positioning?
• Speed of escalation: How quickly could a supply chain issue move from internal escalation to coordinated external action?

Framed this way, the discussion shifts from legal exposure to supply chain governance, and to the board’s role in ensuring that resilience is built into commercial decisions before disruption forces the issue.

The first half of 2026 showed that the window between a supply chain decision and the first class action filing can be uncomfortably short. Investment in contract quality, supplier oversight, and internal escalation pathways reduces liability and, crucially, limits the conditions that allow a supply chain issue to become an enterprise-level event.

For further analysis of the trends underpinning this piece, download the full report here: A Global View on Group Action Litigation: What Lies Ahead?